II. Definitions
- Protease
- Enzyme that breaks peptide bonds
III. Mechanism
- Protease Inhibitors (PI) block viral proteases
- Protease Inhibitors are not limited to HIV Infection management
- In Covid19, Nirmatrelvir/r (Paxlovid) is a Protease Inhibitor
- In the case of HIV, Protease Inhibitors bind the catalytic site of HIV protease
IV. Medications: Boosters
- Most Protease Inhibitors are "boosted" with either Ritonavir or Cobicistat
- As with Protease Inhibitors in general, these boosting agents have numerous Drug Interactions
-
Ritonavir (Norvir)
- Protease Inhibitor used at low dose in combination with other PI (limited by adverse gastrointestinal effects)
- Suffix '/r' added when a protease inhibutor is combined with Ritonavir
-
Cobicistat (Tybost)
- Strong CYP2A4 Inhibitor (also inhibits multiple other metabolic pathways)
- Combined with either Atazanavir and Darunavir
V. Medications: Protease Inhibitors
- Amprenavir (Agenerase)
-
Atazanavir (Reyataz, ATV, ATV/r, or combined with Cobicistat)
- Unboosted (without Ritonavir) has least adverse effect on lipids
-
Darunavir (DRV, DRV/r or combined with Cobicistat)
- Less adverse effects on lipid profile
- Fosamprenavir (Lexiva, FPV or FPV/r)
- Indinavir (Crixivan)
- Lopinavir with Ritonavir (Kaletra, LPV/r)
- Nelfinavir (Viracept)
- Ritonavir (Norvir, /r)
- Saquinavir (Fortovase)
-
Saquinavir
Mesylate (Invirase)
- Precaution: Saquinavir and SaquinavirMesylate are not equivalent
- Tipranavir (Aptivus)
VI. Adverse Effects
- See each individual agent for specific adverse effects
- Nephrolithiasis (Indinavir)
- Severe Diarrhea (Nelfinavir)
- Gastrointestinal upset
- Lipodystrophy
- Osteopenia
- Spontaneous bleeding in Hemophilia
-
Insulin Resistance and Hyperglycemia
- Manage with lifestyle changes (diet, Exercise)
- Consider medications
- Severe lipid abnormalities
- Effects
- Hypertriglyceridemia
- Low HDL
- Management
- Consider Atazanavir (unboosted or boosted) or boosted Darunavir (DRV)
- Can be treated with Pravastatin (see below)
- Resolves with discontinuation of Protease Inhibitor
- Effects
- Hepatotoxicity
- Increased risk with concurrent use of other HIV agents
- Increased risk with comorbid Hepatitis C
- Monitor LFTs every 2 weeks for first month, then every 3 months
VII. Drug Interactions
-
Drug Interactions are common
- Protease Inhibitors cause the most Drug Interactions of all Antiretrovirals
- Use formal Drug Interaction applications when prescribing
- Protease Inhibitors and Cobicistat inhibit CYP3A4 resulting in numerous interactions
-
Statin drugs (used for PI-induced lipid abnormalities)
- Pravastatin is first choice Statin for use with PI
- Rosuvastatin (Crestor) or Atorvastatin (Lipitor) may also be used with caution
- Do not use Simvastatin or Lovastatin with PI
- Apixiban or Rivaroxaban
- Metabolized by CYP3A4 and P-Glycoprotein
- Protease Inhibitors strongly inhibit CYP3A4 or P-Glycoprotein, with associated bleeding risk